Personality
6
Open
6
Cons
5
Extr
6
Agre
4
Neur
Hikal
Healthcare · Small Cap
Mature Stable · Hierarchical
About
Sameer Hiremath is the Managing Director of Hikal, a Small Cap company in the Healthcare sector with a market cap of ₹2K Cr. A Pragmatic leader with 21 years of experience, he is known for consensus-driven decision-making and organic builder strategy. Emphasizes long-term relationship building with global pharma innovators while maintaining R&D-led stability.
FAQ
What is Sameer Hiremath's leadership style?
Sameer Hiremath is classified as a Pragmatic leader. He is consensus-driven in decision-making, with a legacy motivation and steady-marathon pace of execution.
What is Sameer Hiremath's educational background?
Sameer Hiremath holds a B. E Chemical Engineering from MIT Pune (Maharashtra Institute of Technology) (B.E. Chemical Engineering) and a MBA from Boston University, USA.
Who is the CEO of Hikal?
Sameer Hiremath is the Managing Director of Hikal. He has been with the company for 15 years and in the current role for 10 years.
Leadership DNA
ArchetypePragmatic
MotivationLegacy
CrisisSteady Hand
DecisionConsensus-Driven
GrowthOrganic Builder
PeopleInstitution Builder
InnovationFast-Follower
PaceSteady-Marathon
PurposeProfit-Pure
CustomerB2B-Enterprise
EmployerSteady Employer
BrandTechnical-Expert
FocusProduct Innovation
OrientationDeep Specialist
Leadership Evidence
“Emphasizes long-term relationship building with global pharma innovators while maintaining R&D-led stability.”
⚡ Crisis●●●●○
Maintained operational continuity and focus on core B2B pharmaceutical and crop protection segments despite regulatory and governance headwinds.
🎯 Motivation●●●●○
Focuses on sustaining and growing the family-founded business while navigating long-term industry transitions.
👥 People●●●○○
Emphasizes professionalizing the organization and strengthening systems to transition from a promoter-led entity to a sustainable enterprise.
📈 Growth●●●●●
Hikal's growth has been primarily driven by internal capacity expansion and long-term R&D partnerships rather than M&A.
💡 Innovation●●●●○
Hikal focuses on process chemistry and scaling complex generic APIs and intermediates for global innovators rather than pioneering new drug discovery.
🏃 Pace●●●●○
As a long-term supplier to global pharmaceutical companies, its operations are defined by multi-year contracts and predictable, process-driven manufacturing cycles.
🌱 Purpose●●●○○
The company operates primarily as a B2B contract manufacturer where ESG and CSR efforts are largely aligned with regulatory compliance and client audit requirements.
🏷️ Brand●●●●○
The company’s market reputation is built on its deep technical expertise in complex chemical synthesis and its ability to meet stringent global regulatory quality standards.
🤝 Customer●●●●●
Hikal operates as a specialized supplier of Active Pharmaceutical Ingredients and intermediates to large global pharmaceutical and crop protection companies.
💼 Employer●●●○○
It is viewed as a stable, legacy-driven organization in the chemical manufacturing space, offering long-term career paths in technical and plant operations.
📋 Mandate
Modernizing legacy manufacturing processes and supply chains in the pharma sector is critical for sustaining long-term margins.
🏢 Culture●●●○○
Long-established chemical and pharmaceutical player with traditional family-led oversight of operations.
Financials
Revenue FY25₹2K Cr
PAT FY25₹91 Cr
Rev CAGR 5Y-1.4%
OPM10.6%
NPM4.9%
ROE7.2%
ROCE11.2%
P/E—
Fwd P/E21.3
P/B1.8
D/E57.2
Promoter69.1%
Institutional7.7%
Mkt Cap₹2K Cr
Compensation
To Be Published
Data being verified from audited reports
